Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial - Université de Lorraine Access content directly
Journal Articles European Heart Journal: Acute Cardiovascular Care Year : 2022

Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial

John Vincent
  • Function : Author
Paula Abreu
  • Function : Author
Martijn Busselen
  • Function : Author
Wh Wilson Tang
  • Function : Author
Michael Böhm
Bertram Pitt

Abstract

Abstract Aims Magnesium changes are common in myocardial infarction (MI) complicated with left ventricular systolic dysfunction (LVSD) and/or heart failure (HF). The relation between serum magnesium and clinical outcomes is insufficiently elucidated in this population. Methods and results The EPHESUS trial randomized 6632 patients to either eplerenone or placebo. Hypomagnesemia and hypermagnesemia were defined as a serum magnesium <0.66 and >1.10 mmol/L, respectively. Linear mixed models and time-dependent Cox regression analysis were used to determine the effect of eplerenone on magnesium changes and the prognostic importance of magnesium. The co-primary outcomes were all-cause mortality and a composite of cardiovascular (CV) mortality and CV hospitalization. A total of 5371 patients had a post-baseline magnesium measurement. At baseline, 231 (4.3%) patients had hypomagnesemia and 271 (5.0%) patients had hypermagnesemia. During a median follow-up of 16 months, 682 (13%) developed hypomagnesemia and 512 (9.5%) hypermagnesemia. Eplerenone treatment did not result in a different magnesium level during follow-up (P = 0.14). After covariate adjustment hypo- and hypermagnesemia were not associated with a higher risk of CV events. Magnesium levels did not modulate the effect of a high potassium (>5 mmol/L) or low potassium (<4 mmol/L) on the clinical outcome. Baseline magnesium levels did not influence the treatment effect of eplerenone (P-interaction > 0.1 for all primary and secondary endpoints). Conclusion In patients with MI complicated by LVSD or HF, magnesium alterations were not associated with clinical outcomes nor did they influence the effect of eplerenone. Serum magnesium did not modulate the effect of potassium changes on clinical outcome or the treatment effect of eplerenone. ClinicalTrials.gov identifier NCT00232180.
Fichier principal
Vignette du fichier
Magnesium and EPHESUS.pdf (1.57 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03529833 , version 1 (17-01-2022)

Identifiers

Cite

Pieter Martens, João Pedro Ferreira, John Vincent, Paula Abreu, Martijn Busselen, et al.. Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial. European Heart Journal: Acute Cardiovascular Care, 2022, ⟨10.1093/ehjacc/zuab111⟩. ⟨hal-03529833⟩
151 View
146 Download

Altmetric

Share

Gmail Facebook X LinkedIn More